Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
A Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as Delpacibart Zotadirsen) in Participants With DMD With Gene Mutations Amenable to Exon 44 SkippingCongenital, Hereditary, and Neonatal Diseases and Abnormalities, Duchenne muscular dystrophy, Infant, Newborn, Diseases, Muscular Disorders, Atrophic, X-linked disease, congenital, hereditary disease, inherited neurodegenerative disorder, muscle tissue disorder, muscular dystrophy, musculoskeletal system disorder, myotonic dystrophy, myotonic syndrome, nervous system disorder, neurodegenerative disease, neuromuscular diseaseRecruitingPhase 32026-09-29NCT07587242

1 results · Page 1 of 1

Swipe the table sideways for more columns.

OrganizationsLinked trials
Avidity Biosciences, Inc.6

17 results · Page 1 of 1

Swipe the table sideways for more columns.